AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22988894 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous alteplase (0.9 mg/kg)
Number of subjects: 591
Study 22988894 — intervention group
Group type: COMPARATOR
Intervention: Safe Implementation of Thrombolysis in Stroke-Monitoring Study (control group)
Number of subjects: 591
Study 22988894 — intervention group
Group type: COMPARATOR
Intervention: Pooled randomized controlled trials (control group)
Number of subjects: 591
Study 23131886 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 110
Study 23131886 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 110
Study 23131886 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 110
Study 21029890 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherent ocular bandage
Number of subjects: 45
Study 21029890 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study 18024487 — intervention group
Group type: COMPARATOR
Intervention: rFSH alone (Gonal-F)
Number of subjects: 526
Study 18024487 — intervention group
Group type: EXPERIMENTAL
Intervention: rFSH + rLH (Luveris)
Number of subjects: 526
Study 18024487 — intervention group
Group type: COMPARATOR
Intervention: rFSH alone (Gonal-F) with low LH levels (<33 percentile) on Days 1 and 6
Number of subjects: 526
Study 18024487 — intervention group
Group type: EXPERIMENTAL
Intervention: rFSH + rLH (Luveris) with low LH levels (<33 percentile) on Days 1 and 6
Number of subjects: 526
Study 18024487 — intervention group
Group type: EXPERIMENTAL
Intervention: rLH supplementation
Number of subjects: 526
Study 16369154 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective computerized analysis
Number of subjects: 60
Study 16369154 — intervention group
Group type: COMPARATOR
Intervention: Subjective analysis
Number of subjects: 60
Study 11834529 — intervention group
Group type: EXPERIMENTAL
Intervention: FCHL-affected subjects
Number of subjects: 46
Study 10575170 — intervention group
Group type: EXPERIMENTAL
Intervention: IRIV-HAV and YFV
Number of subjects: 105
Study 10575170 — intervention group
Group type: COMPARATOR
Intervention: IRIV-HAV
Number of subjects: 105
Study 10575170 — intervention group
Group type: EXPERIMENTAL
Intervention: YFV
Number of subjects: 105
Study 10575170 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 105
Study 7484486 — intervention group
Group type: EXPERIMENTAL
Intervention: Large Cell Ripplebed (AP)
Number of subjects: 0
Study 7484486 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventix (CLP)
Number of subjects: 0
Study 7484486 — intervention group
Group type: EXPERIMENTAL
Intervention: Groove prototype (CLP)
Number of subjects: 0
Study 7484486 — intervention group
Group type: EXPERIMENTAL
Intervention: Modular Propad (CLP)
Number of subjects: 0
Study 7484486 — intervention group
Group type: EXPERIMENTAL
Intervention: Ardo Watersoft (CLP)
Number of subjects: 0
Study 7484486 — intervention group
Group type: COMPARATOR
Intervention: Spenco (C)
Number of subjects: 0
Study 7484486 — intervention group
Group type: COMPARATOR
Intervention: Surgicgoods Hollowcore Mattress Pad (C)
Number of subjects: 0
Study 1963130 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate of patient enrollment in the Macular Photocoagulation Study (MPS)
Number of subjects: 0
Study 1963130 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate of patient enrollment in the Early Treatment Diabetic Retinopathy Study (ETDRS)
Number of subjects: 0
Study 1963130 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactive patients in the Macular Photocoagulation Study (MPS)
Number of subjects: 0
Study 1963130 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactive patients in the Early Treatment Diabetic Retinopathy Study (ETDRS)
Number of subjects: 0
Study 7015220 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol 0.5%
Number of subjects: 35
Study 7015220 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 31217176 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline levels of oxidized LDL (oxLDL) in circulating immune complexes (LDL‐ICs)
Number of subjects: 0
Study 31217176 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline levels of MDA‐modified LDL (MDA‐LDL) in circulating immune complexes (LDL‐ICs)
Number of subjects: 0
Study 31217176 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline levels of oxLDL‐IC
Number of subjects: 0
Study 31217176 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline levels of modified LDL‐IC
Number of subjects: 0
Study 31217176 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline levels of modified LDL biomarkers
Number of subjects: 0
Study 27650328 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (20 mg/day)
Number of subjects: 41
Study 27650328 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 26807640 — intervention group
Group type: EXPERIMENTAL
Intervention: DC-LOP (IV paclitaxel at 60 mg/m² followed by IV carboplatin at AUC 6 and IV pegylated liposomal doxorubicin at 30 mg/m²)
Number of subjects: 22
Study 26807640 — intervention group
Group type: EXPERIMENTAL
Intervention: GC-LOP (IV paclitaxel at 60 mg/m² followed by IV gemcitabine at 1000 mg/m²)
Number of subjects: 22
Study 26807640 — intervention group
Group type: EXPERIMENTAL
Intervention: DC-LOP
Number of subjects: 22
Study 26807640 — intervention group
Group type: EXPERIMENTAL
Intervention: GC-LOP
Number of subjects: 22
Study 24625922 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group 1)
Number of subjects: 98
Study 24625922 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin for 3 days (group 2)
Number of subjects: 98
Study 24625922 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin for 1 week (group 3)
Number of subjects: 98
Study 24625922 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin for 6 weeks (group 4)
Number of subjects: 98
Study 24625922 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonunion patients
Number of subjects: 98
Study 21142292 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous microdose of verapamil [0.05 mg] (period 1)
Number of subjects: 6
Study 21142292 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous microdose of verapamil [0.05 mg] administered concomitantly with an oral therapeutic dose [80 mg] (period 2)
Number of subjects: 6
Study 21142292 — intervention group
Group type: EXPERIMENTAL
Intervention: (R)‐enantiomer of verapamil
Number of subjects: 6
Study 21142292 — intervention group
Group type: EXPERIMENTAL
Intervention: (S)‐enantiomer of verapamil
Number of subjects: 6
Study 19074961 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated dose of antenatal betamethasone
Number of subjects: 142
Study 19074961 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal growth (weight, length, head circumference)
Number of subjects: 142
Study 16773465 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid mixture (108 g) given orally to cirrhotics
Number of subjects: 29
Study 15222892 — intervention group
Group type: EXPERIMENTAL
Intervention: Rizatriptan (RI)
Number of subjects: 45
Study 15222892 — intervention group
Group type: EXPERIMENTAL
Intervention: Rizatriptan plus rofecoxib (RI + RO)
Number of subjects: 45
Study 15222892 — intervention group
Group type: EXPERIMENTAL
Intervention: Rizatriptan plus tolfenamic acid (RI + TA)
Number of subjects: 45
Study 11181660 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant therapy (5 years of tamoxifen, polychemotherapy including cyclophosphamide/methotrexate/fluorouracil-like regimens, anthracycline-based therapy, or therapy based on both an anthracycline and a taxane)
Number of subjects: 0
Study 11181660 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant! computer program
Number of subjects: 0
Study 9393392 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 0
Study 9393392 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 0
Study 9393392 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 0
Study 7951404 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafarelin acetate 800 micrograms per day
Number of subjects: 213
Study 7951404 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol 800 micrograms per day
Number of subjects: 213
Study 3310669 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 hours of early morning phototherapy
Number of subjects: 16
Study 3310669 — intervention group
Group type: COMPARATOR
Intervention: 2 hours of early afternoon phototherapy
Number of subjects: 16
Study 29614502 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% NaF varnish
Number of subjects: 15
Study 29614502 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% NaF + tricalcium phosphate (TCP) varnish
Number of subjects: 15
Study 29614502 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% NaF + amorphous calcium phosphate (ACP) varnish
Number of subjects: 15
Study 29614502 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 27225722 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral L-carnitine, 1 g/L for 3 months
Number of subjects: 50
Study 27225722 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 50
Study 25140957 — intervention group
Group type: EXPERIMENTAL
Intervention: GS-5806 (50 mg first dose, then 25 mg daily for 4 days)
Number of subjects: 54
Study 25140957 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 23768274 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfredson's exercise programme
Number of subjects: 41
Study 23768274 — intervention group
Group type: COMPARATOR
Intervention: Stanish's exercise programme
Number of subjects: 41
Study 21733370 — intervention group
Group type: EXPERIMENTAL
Intervention: estradiol and drospirenone tablets (Angeliq)
Number of subjects: 244
Study 21733370 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 244
Study 18494340 — intervention group
Group type: EXPERIMENTAL
Intervention: wavefront-optimized LASIK
Number of subjects: 100
Study 18494340 — intervention group
Group type: EXPERIMENTAL
Intervention: customized LASIK
Number of subjects: 100
Study 16473758 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture and herbal medicine
Number of subjects: 5
Study 16473758 — intervention group
Group type: EXPERIMENTAL
Intervention: Promotion of trials to the wider community
Number of subjects: 5
Study 16473758 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial acceptability
Number of subjects: 5
Study 12571165 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin for 6 months followed by clomiphene citrate
Number of subjects: 60
Study 12571165 — intervention group
Group type: COMPARATOR
Intervention: hMG for ovulation induction
Number of subjects: 60
Study 12571165 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effective analysis for medications per pregnancy in group I
Number of subjects: 60
Study 10920060 — intervention group
Group type: EXPERIMENTAL
Intervention: Light to moderate alcohol consumption (rarely/never, monthly, weekly, daily) among nondiabetic men
Number of subjects: 87938
Study 10920060 — intervention group
Group type: EXPERIMENTAL
Intervention: Light to moderate alcohol consumption (rarely/never, monthly, weekly, daily) among diabetic men
Number of subjects: 87938
Study 8751736 — intervention group
Group type: EXPERIMENTAL
Intervention: Embryos grown in groups (study group)
Number of subjects: 91
Study 8751736 — intervention group
Group type: COMPARATOR
Intervention: Embryos grown individually (control group)
Number of subjects: 91
Study 1566986 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tubocurarine 0.05 mg.kg‐1
Number of subjects: 120
Study 1566986 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous chlorpromazine 0.1 mg.kg‐1
Number of subjects: 120
Study 1566986 — intervention group
Group type: EXPERIMENTAL
Intervention: Alphatocopherol (vitamin E) 600 mg in three divided doses orally
Number of subjects: 120
Study 1566986 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 600 mg orally
Number of subjects: 120
Study 1566986 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous calcium chloride 5 mg.kg‐1
Number of subjects: 120
Study 1566986 — intervention group
Group type: COMPARATOR
Intervention: No pretreatment
Number of subjects: 120
Study 3905182 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol
Number of subjects: 0
Study 3905182 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30986285 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted implant planning based on three-dimensional (3D) computer-tomography (test group 1, n = 24)
Number of subjects: 73
Study 30986285 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted implant planning based on three-dimensional (3D) computer-tomography (test group 2, n = 23)
Number of subjects: 73
Study 30986285 — intervention group
Group type: COMPARATOR
Intervention: Conventional two-dimensional radiograph and free-hand implant placement (control, n = 26)
Number of subjects: 73
Study 28855085 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist accelerometer (ActiGraph GT3X+), pedometer-assessed step counts (Yamax SW-200, 7 days)
Number of subjects: 366
Study 28855085 — intervention group
Group type: COMPARATOR
Intervention: Wrist accelerometer (ActiGraph GT3X+), pedometer-assessed step counts
Number of subjects: 366
Study 28855085 — intervention group
Group type: COMPARATOR
Intervention: Wrist group participants
Number of subjects: 366
Study 26864301 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment of fractional 1550-nm ytterbium/erbium fiber laser and 0.1% tacrolimus ointment
Number of subjects: 120
Study 26864301 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 120
Study 26864301 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment
Number of subjects: 120
Study 22907761 — intervention group
Group type: EXPERIMENTAL
Intervention: Fesoterodine 8 mg
Number of subjects: 4208
Study 22907761 — intervention group
Group type: COMPARATOR
Intervention: Tolterodine ER 4 mg
Number of subjects: 4208
Study 22907761 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4208
Study 20123821 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care for depression
Number of subjects: 906
Study 20123821 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple assessments (baseline, three months, six months, and 12 months)
Number of subjects: 906
Study 17544560 — intervention group
Group type: EXPERIMENTAL
Intervention: elmex Sensitive Extra Soft (ESES)
Number of subjects: 84
Study 17544560 — intervention group
Group type: EXPERIMENTAL
Intervention: elmex Sensitive Soft (ESS)
Number of subjects: 84
Study 17544560 — intervention group
Group type: COMPARATOR
Intervention: ADA standard toothbrush (ADAS)
Number of subjects: 84
Study 15213039 — intervention group
Group type: COMPARATOR
Intervention: Lutein supplement in oil (LS treatment, 1.7 mg lutein/d)
Number of subjects: 9
Study 15213039 — intervention group
Group type: EXPERIMENTAL
Intervention: Yellow carrots (YC treatment, 1.7 mg lutein/d)
Number of subjects: 9
Study 15213039 — intervention group
Group type: COMPARATOR
Intervention: White carrots (WC treatment, 0 mg lutein/d)
Number of subjects: 9
Study 15213039 — intervention group
Group type: EXPERIMENTAL
Intervention: Yellow carrots (YC treatment)
Number of subjects: 9
Study 15213039 — intervention group
Group type: COMPARATOR
Intervention: Lutein supplement in oil (LS treatment)
Number of subjects: 9
Study 11448369 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy (IPT)
Number of subjects: 28
Study 11448369 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine hydrochloride (37.5 mg twice-daily)
Number of subjects: 28
Study 9539918 — intervention group
Group type: EXPERIMENTAL
Intervention: Griseofulvin (10 mg/kg/day for 8 weeks)
Number of subjects: 24
Study 9539918 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine (62.5‐250 mg/day for 4 weeks)
Number of subjects: 24
Study 8024798 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical all-trans retinoic acid gel (Aberel)
Number of subjects: 0
Study 8024798 — intervention group
Group type: COMPARATOR
Intervention: Salicylic acid gel
Number of subjects: 0
Study 8024798 — intervention group
Group type: COMPARATOR
Intervention: Gel vehicle
Number of subjects: 0
Study 8024798 — intervention group
Group type: COMPARATOR
Intervention: Untreated skin
Number of subjects: 0
Study 2478341 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlormadinone acetate (CMA), 5 mg/day
Number of subjects: 12
Study 2478341 — intervention group
Group type: COMPARATOR
Intervention: Previous study with 50 mg/day CMA
Number of subjects: 12
Study 7375 — intervention group
Group type: EXPERIMENTAL
Intervention: bromazepam (9 mg)
Number of subjects: 13
Study 7375 — intervention group
Group type: EXPERIMENTAL
Intervention: diazepam (10 mg)
Number of subjects: 13
Study 7375 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 13
Study 29947134 — intervention group
Group type: EXPERIMENTAL
Intervention: Bakuchiol 0.5% cream applied twice daily
Number of subjects: 44
Study 29947134 — intervention group
Group type: COMPARATOR
Intervention: Retinol 0.5% cream applied daily
Number of subjects: 44
Study 28327054 — intervention group
Group type: EXPERIMENTAL
Intervention: Low frequency (LF) rTMS + physical therapy (PT)
Number of subjects: 25
Study 28327054 — intervention group
Group type: EXPERIMENTAL
Intervention: Low frequency (LF) rTMS + NMES + physical therapy (PT)
Number of subjects: 25
Study 28327054 — intervention group
Group type: COMPARATOR
Intervention: Physical therapy (PT) only
Number of subjects: 25
Study 26126419 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Adaptation Training (CAT) weekly for 9 months; monthly thereafter
Number of subjects: 120
Study 26126419 — intervention group
Group type: COMPARATOR
Intervention: Generic environmental supports
Number of subjects: 120
Study 26126419 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 120
Study 26126419 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Adaptation Training (CAT)
Number of subjects: 120
Study 23535290 — intervention group
Group type: EXPERIMENTAL
Intervention: Integration of HIV care into primary care (high scores for total integration)
Number of subjects: 9252
Study 23535290 — intervention group
Group type: EXPERIMENTAL
Intervention: Integration of HIV care into primary care (ART integration)
Number of subjects: 9252
Study 23535290 — intervention group
Group type: EXPERIMENTAL
Intervention: Integration of HIV care into primary care (internal integration)
Number of subjects: 9252
Study 23535290 — intervention group
Group type: EXPERIMENTAL
Intervention: Integration of HIV care into primary care (total integration)
Number of subjects: 9252
Study 23535290 — intervention group
Group type: EXPERIMENTAL
Intervention: Integration of HIV care into primary care (pre-ART integration)
Number of subjects: 9252
Study 23535290 — intervention group
Group type: EXPERIMENTAL
Intervention: Integration of HIV care into primary care (mainstreaming HIV)
Number of subjects: 9252
Study 22013172 — intervention group
Group type: EXPERIMENTAL
Intervention: I-125 brachytherapy
Number of subjects: 0
Study 22013172 — intervention group
Group type: COMPARATOR
Intervention: Enucleation
Number of subjects: 0
Study 19179111 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual follow-up visits by a specialist nurse
Number of subjects: 200
Study 19179111 — intervention group
Group type: COMPARATOR
Intervention: Physician-led visits including oximetry
Number of subjects: 200
Study 16507179 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (administered in small, divided doses over 4-5 min until Wilson sedation score reached three)
Number of subjects: 38
Study 16254093 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance-approach goal
Number of subjects: 0
Study 16254093 — intervention group
Group type: COMPARATOR
Intervention: Mastery goal (standard)
Number of subjects: 0
Study 16254093 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulated mastery goal (more difficult)
Number of subjects: 0
Study 12173139 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (3 mg retinol equivalent)
Number of subjects: 697
Study 12173139 — intervention group
Group type: COMPARATOR
Intervention: Control (iron and folate alone)
Number of subjects: 697
Study 9949754 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (cessation intervention)
Number of subjects: 16
Study 9949754 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 16
Study 7582385 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 5 mg (0.32 +/- 0.07 mg.kg‐1) as a 10 mg.ml‐1 solution
Number of subjects: 8
Study 2316832 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 7 micrograms/kg via a central venous catheter
Number of subjects: 110
Study 2316832 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 7 micrograms/kg through a peripheral venous cannula
Number of subjects: 110
Study 2316832 — intervention group
Group type: COMPARATOR
Intervention: Sterile water via a central venous catheter
Number of subjects: 110
Study 350498 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylcysteine hydrochloride (1200 mg daily in Week 1, 800 mg daily in Week 2, then 600 mg daily)
Number of subjects: 30
Study 350498 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical tablets, same regimen)
Number of subjects: 30
Study 31001695 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer survivors (5 years after diagnosis)
Number of subjects: 1002
Study 31001695 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer survivors (10 years after diagnosis)
Number of subjects: 1002
Study 31001695 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer survivors younger than 60 years
Number of subjects: 1002
Study 31001695 — intervention group
Group type: EXPERIMENTAL
Intervention: Women cancer survivors
Number of subjects: 1002
Study 31001695 — intervention group
Group type: EXPERIMENTAL
Intervention: Elderly cancer survivors
Number of subjects: 1002
Study 31001695 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial problems, global quality of life, cognitive function
Number of subjects: 1002
Study 30893645 — intervention group
Group type: EXPERIMENTAL
Intervention: HMUFA diet
Number of subjects: 486
Study 30893645 — intervention group
Group type: EXPERIMENTAL
Intervention: HSFA diet
Number of subjects: 486
Study 30893645 — intervention group
Group type: EXPERIMENTAL
Intervention: LFHCC n‐3
Number of subjects: 486